Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (2842)	9/24/2011 8:45:13 AM
From: IRWIN JAMES FRANKEL	Respond to of 3027

>>I see that Sandoz is part of the suit with Momenta. I wonder if that precludes Momenta from arguing severe harm if allowed to be marketed. No it won't. >>What happens if no injunction but they win the suit? Royalty model still? This part is less clear to me since I do not know the criteria by which the court determines what remedy to fashion. If MNTA were to "win", the court would fashion a remedy for the wrong done and another remedy for prospective harm that could be done: - money damages for infringing sales; - - block further sales by injunction; or - - a royalty on further sales ij